MaxCyte, Inc. Inducement Grants (5037L)
May 16 2022 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5037L
MaxCyte, Inc.
16 May 2022
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule
5635(c)(4)
GAITHERSBURG, MD, May 16, 2022 - MaxCyte, Inc., (NASDAQ: MXCT;
LSE: MXCT), a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization, today announced that,
on May 10, 2022, the Compensation Committee of MaxCyte's Board of
Directors granted stock options to purchase an aggregate of 73,700
shares of MaxCyte's common stock to six (6) newly hired employees.
The stock options were granted as material inducements to
employment with MaxCyte in accordance with Nasdaq Listing Rule
5635(c)(4) and were granted under the MaxCyte, Inc. 2021 Inducement
Plan (the "2021 Inducement Plan").
The stock options have a ten-year term and an exercise price of
$4.81 per share, which is equal to the closing price of MaxCyte's
common stock on May 10, 2022. Each option will vest over a
four-year period, with 25% of the shares vesting after 12 months
and the remaining shares vesting monthly over the following 36
months, subject to the employee's continued employment with MaxCyte
on such vesting dates. The options are subject to the terms and
conditions of the 2021 Inducement Plan and the terms and conditions
of an award agreement covering the grants.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM)
GTx(TM)and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
+44 (0)203 709 5700
UK IR Adviser maxcyte@consilium-comms.com
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCAJMATMTMBBTT
(END) Dow Jones Newswires
May 16, 2022 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024